In laboratory and pre-clinical research settings, native GLP-1 serves as the primary pharmacological reference standard for studying GLP-1 receptor binding, activation, and downstream signalling as well as the broader incretin axis and its connections to pancreatic -cell biology, appetite regulation, gastric motility, cardiovascular function, and neuroprotection
The FDA guidance, Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics (June 2024), requires product-specific immunogenicity assessments that consider the base sequence, chemical modifications, conjugation chemistry, strandedness, distribution to target tissues, and dosing frequency
The compound is identified by CAS Number 170851-70-4 and features a well-defined molecular structure with the formula CHNO and a molecular weight of 711.85 g/mol
& Nedergaard, M